The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Background:
- The prevalence of arthritis which needs celecoxib prescription is high in patients with
coronary artery disease.
- The main concern is that celecoxib would increase thrombogenicity by inhibiting the
synthesis of prostacyclin in endothelial cells.
- It is not known whether the administration of celecoxib would deteriorate antiplatelet
effects of aspirin and clopidogrel which are used after stenting.
Methods:
- Healthy volunteers (n=40)
- Randomization into five subgroups
- aspirin, celecoxib, aspirin+celecoxib, aspirin+clopidogrel,
aspirin+clopidogrel+celecoxib
- Medication schedule : medication of each drug for 6 days, blood samples at day 0 and day
7
- Celecoxib 200mg twice a day, and/or aspirin 100mg daily, and/or clopidogrel 75 mg daily
- Platelet function test : light transmittance aggregometry and arachidonic acid
metabolite assay among subgroups.
Study hypothesis : The addition of celecoxib does not deteriorate antiplatelet function of
aspirin and clopidogrel.